We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 140.00
Bid: 135.00
Ask: 145.00
Change: 12.50 (9.80%)
Spread: 10.00 (7.407%)
Open: 127.50
High: 140.00
Low: 127.50
Prev. Close: 127.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Aug 2019 09:33

RNS Number : 4760J
Faron Pharmaceuticals Oy
19 August 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Timo Syrjälä

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

05.08.2019

6. Date on which issuer notified (DD/MM/YYYY):

15.08.2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.36%

 

14.36%

38.175.734

Position of previous notification (if

applicable)

13.11%

 

13.11%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

FI4000153309

2.205.025

3.275.350

5.78%

8.58%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

5.480.375

14.36%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Timo Syrjälä (Direct)

5.78%

5.78%

Acme Investments SPF Sarl (Indirect)

8.58%

 

8.58%

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi  Threshold announced in company stock market release 5.8.2019

 

     

 

Place of completion

Lausanne

Date of completion

15/08/2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFMGMRRLGGLZG
Date   Source Headline
27th Jul 20207:00 amRNSChange of Adviser
20th Jul 20204:41 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
8th Jul 20203:00 pmRNSManagers’ transactions
16th Jun 20207:01 amRNSFaron hosts virtual R&D Day today
16th Jun 20207:00 amRNSFaron update on pipeline progress ahead of R&D Day
15th Jun 20207:00 amRNSFaron receives EUR 2.1 million funding from BF
11th Jun 20207:00 amRNSFaron selected for EUR2.5 million grant from EIC
1st Jun 20207:00 amRNSMATINS Update
28th May 20207:00 amRNSFaron announces R&D Day to be held in June
20th May 20207:00 amRNSPublication in Intensive Care Medicine
18th May 20204:00 pmRNSResults of the Annual General Meeting
13th May 20201:00 pmRNSExercise of options
12th May 20206:00 pmRNSManagers’ transactions
11th May 202010:00 amRNSFaron receives grant from Business Finland
5th May 20207:00 amRNSClevegen manufacturing agreement
29th Apr 20201:15 pmRNSHolding(s) in Company
27th Apr 20202:45 pmRNSHolding(s) in Company
27th Apr 20207:00 amRNSTraumakine to be a part of WHO’s Solidarity trial
23rd Apr 20201:00 pmRNSUpdate on results of Placing and issue of equity
22nd Apr 20207:00 amRNSResult of placing and issue price
21st Apr 20204:45 pmRNSProposed Placing
15th Apr 202011:06 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSNotice of Annual General Meeting
3rd Apr 20202:45 pmRNSAGM to be postponed
1st Apr 20207:00 amRNSREMAP-CAP to study IFN beta-1a effect in COVID-19
30th Mar 20207:00 amRNSPart 1 of the MATINS Phase I/II Study Completed
26th Mar 202010:00 amRNSCorrection to Faron´s Annual Report 2019
25th Mar 20207:28 amRNSFaron´s Annual Report 2019 published
20th Mar 202011:30 amRNSNotice of Annual General Meeting
20th Mar 20207:00 amRNSFinal Results for the year ended December 31, 2019
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:38 pmRNSPrice Monitoring Extension
9th Mar 20207:00 amRNSFDA accepts protocol for new Traumakine trial
5th Mar 20207:00 amRNSMATINS update
2nd Mar 20207:00 amRNSFaron to acquire AOC3 antagonist platform
26th Feb 20207:05 amRNSPrice Monitoring Extension
26th Feb 20207:01 amRNSSecond Price Monitoring Extn
26th Feb 20207:00 amRNSPrice Monitoring Extension
25th Feb 20202:05 pmRNSSecond Price Monitoring Extn
25th Feb 20202:00 pmRNSPrice Monitoring Extension
25th Feb 202011:00 amRNSPrice Monitoring Extension
24th Feb 20204:41 pmRNSSecond Price Monitoring Extn
24th Feb 20204:35 pmRNSPrice Monitoring Extension
18th Feb 202011:06 amRNSSecond Price Monitoring Extn
18th Feb 202011:00 amRNSPrice Monitoring Extension
18th Feb 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.